Front Row Advisors LLC Bio N Tech Se Transaction History
Front Row Advisors LLC
- $276 Million
- Q2 2025
A detailed history of Front Row Advisors LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Front Row Advisors LLC holds 80 shares of BNTX stock, worth $8,551. This represents 0.0% of its overall portfolio holdings.
Number of Shares
80Holding current value
$8,551% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BNTX
# of Institutions
320Shares Held
40.9MCall Options Held
1.37MPut Options Held
1.52M-
Baillie Gifford & CO8.04MShares$859 Million0.67% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$452 Million1.88% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$428 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$385 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$203 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.9B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...